Carvedilol Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Carvedilol
Therapeutic Class: Beta-blocker
Subclass: Non-selective beta-blocker with alpha-1 blocking activity
Speciality: Cardiology
Subclass: Non-selective beta-blocker with alpha-1 blocking activity
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
• Extended-release tablets: NOT AVAILABLE in India
Route(s): Oral
Formulations Available in India:
• Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg
• Extended-release tablets: NOT AVAILABLE in India
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Hypertension (Essential)
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on blood pressure response |
|
Usual maintenance dose
|
12.5–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
Clinical Notes:
• Alpha-blocking property provides additional vasodilation — more potent blood pressure lowering than pure beta-blockers
• Elderly patients may respond adequately to 6.25 mg twice daily
• Take with food to reduce risk of orthostatic hypotension
• Monitor standing blood pressure during initiation
• Alpha-blocking property provides additional vasodilation — more potent blood pressure lowering than pure beta-blockers
• Elderly patients may respond adequately to 6.25 mg twice daily
• Take with food to reduce risk of orthostatic hypotension
• Monitor standing blood pressure during initiation
▶ Chronic Heart Failure (NYHA Class II–IV; stable, compensated)
| Parameter | Recommendation |
|
Starting dose
|
3.125 mg twice daily for 2 weeks (initiate only in euvolemic, stable CHF) |
|
Titration
|
Double dose every 2 weeks as tolerated |
|
Usual maintenance dose
|
25 mg twice daily (patients <85 kg); 50 mg twice daily (patients >85 kg) |
|
Maximum dose
|
25 mg twice daily (<85 kg); 50 mg twice daily (>85 kg) |
Clinical Notes:
• Initiate only when patient is stable on optimal doses of ACE inhibitors/ARBs and diuretics
• Should be initiated under specialist supervision or with cardiology guidance
• Transient worsening of heart failure symptoms may occur during up-titration — manage with diuretic adjustment rather than discontinuing carvedilol
• Do not initiate in acutely decompensated heart failure or patients requiring IV inotropes
• Proven mortality benefit in CHF (COPERNICUS, COMET trials)
• Initiate only when patient is stable on optimal doses of ACE inhibitors/ARBs and diuretics
• Should be initiated under specialist supervision or with cardiology guidance
• Transient worsening of heart failure symptoms may occur during up-titration — manage with diuretic adjustment rather than discontinuing carvedilol
• Do not initiate in acutely decompensated heart failure or patients requiring IV inotropes
• Proven mortality benefit in CHF (COPERNICUS, COMET trials)
▶ Angina Pectoris (Chronic Stable)
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on heart rate and symptom control |
|
Usual maintenance dose
|
12.5–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
Clinical Notes:
• Reduces myocardial oxygen demand via heart rate and contractility reduction
• Alpha-blocking effect may provide additional benefit through coronary vasodilation
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
• Reduces myocardial oxygen demand via heart rate and contractility reduction
• Alpha-blocking effect may provide additional benefit through coronary vasodilation
• Avoid abrupt discontinuation — may precipitate angina or myocardial infarction
Secondary Indications — Adults (Off-label, if any)
▶ Left Ventricular Dysfunction Post-Myocardial Infarction — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily (initiate 3–21 days post-MI when haemodynamically stable) |
|
Titration
|
Double dose every 3–10 days as tolerated |
|
Usual maintenance dose
|
25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
|
Duration
|
Long-term; in combination with ACE inhibitor and statin |
• Specialist only — initiate under cardiology guidance
• Evidence basis: CAPRICORN trial; Indian specialist cardiology practice; meta-analysis level evidence
• Evidence basis: CAPRICORN trial; Indian specialist cardiology practice; meta-analysis level evidence
▶ Portal Hypertension in Cirrhosis (Primary/Secondary Prophylaxis of Variceal Bleeding) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
6.25 mg twice daily |
|
Titration
|
Increase based on heart rate and blood pressure; aim for HR 55–60 bpm while maintaining systolic BP >90 mmHg |
|
Usual maintenance dose
|
6.25–12.5 mg twice daily |
|
Maximum dose
|
12.5 mg twice daily (limited by hypotension in cirrhosis) |
|
Duration
|
Long-term prophylaxis |
• Specialist only — under gastroenterology/hepatology supervision
• Evidence basis: Emerging evidence suggests carvedilol may be more effective than propranolol for HVPG reduction; Indian hepatology practice increasingly using carvedilol
• Note: Lower doses used compared to non-cirrhotic patients due to reduced hepatic metabolism
• Evidence basis: Emerging evidence suggests carvedilol may be more effective than propranolol for HVPG reduction; Indian hepatology practice increasingly using carvedilol
• Note: Lower doses used compared to non-cirrhotic patients due to reduced hepatic metabolism
▶ Atrial Fibrillation (Rate Control) — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
3.125–6.25 mg twice daily |
|
Titration
|
Increase every 1–2 weeks based on ventricular rate control |
|
Usual maintenance dose
|
6.25–25 mg twice daily |
|
Maximum dose
|
25 mg twice daily |
|
Target
|
Resting heart rate <110 bpm (lenient) or <80 bpm (strict) |
• Evidence basis: Indian cardiology practice; useful when heart failure coexists with atrial fibrillation
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not formally approved for paediatric indications in India.
Secondary Indications — Paediatric Doses (Off-label, if any)
▶ Paediatric Heart Failure / Dilated Cardiomyopathy — OFF-LABEL
| Parameter | Recommendation |
|
Starting dose
|
0.05 mg/kg/dose twice daily |
|
Titration
|
Increase every 1–2 weeks as tolerated; double dose at each step |
|
Usual maintenance dose
|
0.2–0.4 mg/kg/dose twice daily (0.4–0.8 mg/kg/day total) |
|
Maximum dose
|
0.5 mg/kg/dose twice daily (1 mg/kg/day total) |
|
Minimum age
|
Not recommended below 2 years except under paediatric cardiologist guidance |
• Specialist only — requires paediatric cardiology supervision
• Evidence basis: Limited paediatric data; extrapolated from adult CHF evidence; Indian paediatric cardiology practice
• Evidence basis: Limited paediatric data; extrapolated from adult CHF evidence; Indian paediatric cardiology practice
Safety Monitoring:
• Blood pressure and heart rate monitoring at each visit during up-titration
• Monitor for signs of worsening heart failure (weight gain, oedema, respiratory distress)
• ECG at baseline and periodically
• Assess growth parameters with long-term use
• Blood pressure and heart rate monitoring at each visit during up-titration
• Monitor for signs of worsening heart failure (weight gain, oedema, respiratory distress)
• ECG at baseline and periodically
• Assess growth parameters with long-term use
Clear statement: Use in children is off-label and restricted to specialist paediatric cardiology centres. Not recommended below 2 years of age.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild to moderate impairment (CrCl >30 mL/min) | No dose adjustment required |
| Severe impairment (CrCl <30 mL/min) | Use with caution; monitor closely for bradycardia and hypotension |
| Haemodialysis | Not significantly dialysed; no supplemental dose required |
Note: Carvedilol is hepatically metabolised — renal impairment has minimal impact on pharmacokinetics.
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment | Start cautiously at 3.125 mg twice daily; slower titration |
| Moderate impairment | Use lower starting doses (3.125 mg twice daily); titrate very slowly; monitor closely for hypotension |
| Severe impairment |
Avoid use — significantly increased drug exposure and risk of adverse effects; contraindicated in patients with clinically evident hepatic impairment
|
CONTRAINDICATIONS
• Second or third-degree atrioventricular block (without pacemaker)
• Severe sinus bradycardia (<50 bpm)
• Sick sinus syndrome (without pacemaker)
• Cardiogenic shock
• Acute decompensated heart failure requiring intravenous inotropic support
• Severe hypotension (systolic BP <85 mmHg)
• Bronchial asthma or history of severe bronchospasm
• Severe chronic obstructive pulmonary disease with bronchospastic component
• Clinically manifest hepatic impairment (Child-Pugh Class B or C)
• Known hypersensitivity to carvedilol or any excipient
• Prinzmetal variant angina (pure vasospastic angina)
• Untreated phaeochromocytoma
• Severe sinus bradycardia (<50 bpm)
• Sick sinus syndrome (without pacemaker)
• Cardiogenic shock
• Acute decompensated heart failure requiring intravenous inotropic support
• Severe hypotension (systolic BP <85 mmHg)
• Bronchial asthma or history of severe bronchospasm
• Severe chronic obstructive pulmonary disease with bronchospastic component
• Clinically manifest hepatic impairment (Child-Pugh Class B or C)
• Known hypersensitivity to carvedilol or any excipient
• Prinzmetal variant angina (pure vasospastic angina)
• Untreated phaeochromocytoma
CAUTIONS
• Diabetes mellitus — may mask hypoglycaemia symptoms (tachycardia, tremor); monitor glucose closely
• Mild to moderate COPD without bronchospastic component — use with caution; start at lowest dose
• Peripheral vascular disease — may exacerbate claudication symptoms
• Thyrotoxicosis — may mask tachycardia; do not withdraw abruptly after thyroid control
• First-degree AV block — use with caution
• Concomitant digoxin or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) — risk of AV block and bradycardia
• Psoriasis — may worsen or trigger psoriatic lesions
• Depression — beta-blockers may exacerbate mood disorders
• Myasthenia gravis — may worsen muscle weakness
• History of severe anaphylactic reactions — may blunt response to epinephrine
• Abrupt withdrawal — taper gradually over 1–2 weeks to avoid rebound tachycardia, hypertension, or angina
• Elderly patients — increased sensitivity; start low and titrate slowly
• Mild to moderate COPD without bronchospastic component — use with caution; start at lowest dose
• Peripheral vascular disease — may exacerbate claudication symptoms
• Thyrotoxicosis — may mask tachycardia; do not withdraw abruptly after thyroid control
• First-degree AV block — use with caution
• Concomitant digoxin or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) — risk of AV block and bradycardia
• Psoriasis — may worsen or trigger psoriatic lesions
• Depression — beta-blockers may exacerbate mood disorders
• Myasthenia gravis — may worsen muscle weakness
• History of severe anaphylactic reactions — may blunt response to epinephrine
• Abrupt withdrawal — taper gradually over 1–2 weeks to avoid rebound tachycardia, hypertension, or angina
• Elderly patients — increased sensitivity; start low and titrate slowly
PREGNANCY
| Consideration | Recommendation |
| Overall safety | Use only if clearly needed and benefits outweigh risks; crosses placenta |
| Risk | Fetal bradycardia, hypoglycaemia, intrauterine growth restriction, hypotension |
| Preferred alternatives | Labetalol (first choice for hypertension in pregnancy); methyldopa |
| When it may be used | Only under obstetric and cardiology specialist supervision if preferred alternatives not suitable |
| Monitoring | Fetal growth (serial ultrasound), fetal heart rate; neonatal heart rate, blood pressure, and glucose monitoring for 48–72 hours post-delivery |
LACTATION
| Consideration | Recommendation |
| Compatibility | Compatible with breastfeeding with caution |
| Drug levels in milk | Low (minimal transfer expected) |
| Preferred alternatives | Labetalol, propranolol, metoprolol (more breastfeeding data available) |
| Infant monitoring | Heart rate, feeding difficulties, lethargy, poor weight gain, signs of beta-blockade |
• Monitor infant closely during first 2 weeks of maternal therapy
ELDERLY
| Consideration | Recommendation |
| Starting dose | 3.125 mg twice daily |
| Titration | Slower titration required — increase dose at 2–4 week intervals |
| Risks | Orthostatic hypotension, dizziness, bradycardia, falls, fatigue, cognitive effects |
| Monitoring | Standing blood pressure, heart rate, renal function |
• Alpha-blocking property increases risk of first-dose orthostatic hypotension — counsel patients
• Assess fall risk before initiation
• Elderly may respond adequately to lower maintenance doses
• Assess fall risk before initiation
• Elderly may respond adequately to lower maintenance doses
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Verapamil, Diltiazem | Additive negative chronotropic and dromotropic effects; increased risk of severe bradycardia, AV block, heart failure |
Avoid combination or use with extreme caution; ECG monitoring required
|
| Amiodarone | Additive bradycardia and conduction abnormalities |
Use with caution; regular ECG and heart rate monitoring
|
| Digoxin | Carvedilol increases digoxin levels (by ~15%); additive bradycardia |
Monitor digoxin levels and heart rate; consider digoxin dose reduction
|
| CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) | Increased carvedilol plasma levels via inhibition of metabolism |
Monitor for excessive beta-blockade; consider dose reduction
|
| Clonidine | Risk of severe rebound hypertension if clonidine stopped abruptly |
Discontinue carvedilol several days before stopping clonidine; taper clonidine slowly
|
| Insulin and sulfonylureas | Beta-blockade masks hypoglycaemia symptoms (tachycardia, tremor) |
Monitor blood glucose closely; educate patient on hypoglycaemia signs
|
| MAOIs | Risk of severe hypertension |
Avoid combination
|
| Class I antiarrhythmics (quinidine, disopyramide, flecainide) | Additive negative inotropic and conduction effects |
Avoid or use with extreme caution
|
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect / Mechanism | Recommendation |
| Rifampicin | May significantly reduce carvedilol efficacy via CYP induction | Monitor blood pressure and heart rate; may need dose adjustment |
| NSAIDs | May attenuate antihypertensive effect via prostaglandin inhibition and sodium retention | Monitor blood pressure |
| Cimetidine | May increase carvedilol levels | Monitor for excessive beta-blockade |
| Cyclosporine | Carvedilol may increase cyclosporine levels | Monitor cyclosporine levels |
| Anaesthetic agents | Enhanced hypotensive effect | Inform anaesthetist; do not discontinue abruptly before surgery |
| Tricyclic antidepressants | Additive orthostatic hypotension | Monitor blood pressure |
| Alpha-blockers (prazosin, doxazosin) | Additive hypotensive effect and orthostatic hypotension | Use with caution; consider dose reduction |
| Antidiabetic agents (other than insulin/sulfonylureas) | May alter glycaemic control | Monitor blood glucose |
| Alcohol | Additive hypotensive effects | Advise moderation |
| Sildenafil and other PDE5 inhibitors | Additive hypotensive effect | Use with caution; monitor blood pressure |
COMMON ADVERSE EFFECTS
• Dizziness
• Fatigue
• Headache
• Bradycardia
• Hypotension (including orthostatic hypotension)
• Diarrhoea
• Nausea
• Weight gain (particularly in heart failure patients)
• Cold extremities
• Oedema (during heart failure initiation)
• Asthenia
• Visual disturbances
• Fatigue
• Headache
• Bradycardia
• Hypotension (including orthostatic hypotension)
• Diarrhoea
• Nausea
• Weight gain (particularly in heart failure patients)
• Cold extremities
• Oedema (during heart failure initiation)
• Asthenia
• Visual disturbances
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Note |
| Severe bradycardia or AV block | May require dose reduction, discontinuation, or temporary pacing; atropine may be needed |
| Worsening heart failure | May occur during initiation/up-titration; manage with diuretic adjustment; temporary dose reduction may be needed |
| Bronchospasm | Discontinue immediately if significant; more likely in patients with reactive airway disease |
| Severe hypotension / Syncope | Particularly with first dose or during up-titration; may require dose reduction |
| Hepatic dysfunction | Rare elevation in transaminases; discontinue if ALT/AST >3× ULN with symptoms |
| Stevens-Johnson Syndrome / Toxic epidermal necrolysis | Rare; discontinue immediately and seek emergency care |
| Acute renal failure | In severe heart failure with renal hypoperfusion |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Blood pressure (supine and standing), heart rate, ECG (if cardiac history), liver function tests, renal function, weight, blood glucose (in diabetics) |
|
During up-titration
|
Blood pressure and heart rate at each dose increase (weekly during titration); weight; signs and symptoms of worsening heart failure |
|
Long-term
|
Blood pressure, heart rate every visit; liver function tests every 6 months; periodic renal function; weight; symptoms of heart failure progression |
Heart failure specific:
• Assess for fluid retention (oedema, weight gain, dyspnoea) at each visit during titration
• Do not up-titrate if signs of decompensation present
• Assess for fluid retention (oedema, weight gain, dyspnoea) at each visit during titration
• Do not up-titrate if signs of decompensation present
BRANDS AVAILABLE IN INDIA
Single-ingredient formulations:
• Cardivas (Sun Pharma)
• Carloc (Torrent Pharmaceuticals)
• Carvedon (Zydus Cadila)
• Carca (Cipla)
• Carvil (Lupin)
• Carvipress (Abbott)
• Coreg (limited availability)
• Multiple generic brands widely available
• Cardivas (Sun Pharma)
• Carloc (Torrent Pharmaceuticals)
• Carvedon (Zydus Cadila)
• Carca (Cipla)
• Carvil (Lupin)
• Carvipress (Abbott)
• Coreg (limited availability)
• Multiple generic brands widely available
Note: Extended-release formulations (Coreg CR equivalent) are NOT AVAILABLE in India
PRICE RANGE (INR)
| Strength | Approximate Price Range (per tablet) |
| 3.125 mg | ₹1–₹2 |
| 6.25 mg | ₹2–₹4 |
| 12.5 mg | ₹3–₹6 |
| 25 mg | ₹5–₹10 |
• Not included in NLEM
• Not under NPPA price control
• Generic versions significantly cheaper than branded
• Widely available in both government and private sector
• Not under NPPA price control
• Generic versions significantly cheaper than branded
• Widely available in both government and private sector
CLINICAL PEARLS
• Start low, go slow in heart failure — initiate at 3.125 mg twice daily and double dose every 2 weeks; rushing titration increases risk of decompensation
• Carvedilol has proven mortality benefit in heart failure (COPERNICUS, COMET trials) — ensure all eligible CHF patients are up-titrated to target doses
• Do not initiate in acutely decompensated heart failure — patient must be euvolemic and stable on diuretics before starting
• Alpha-blocking property causes more pronounced blood pressure lowering and orthostatic hypotension compared to pure beta-blockers — take with food to reduce first-dose effect
• In portal hypertension, carvedilol may be more effective than propranolol for reducing hepatic venous pressure gradient, but use lower doses due to reduced hepatic metabolism in cirrhosis
• Never stop abruptly — taper over 1–2 weeks to avoid rebound tachycardia, hypertension, or precipitation of angina/MI
• Non-selective beta-blocking may worsen bronchospasm — avoid in asthma; use with extreme caution in COPD without bronchospastic component
TAGS
carvedilol; beta-blocker; non-selective; alpha-blocker; heart failure; hypertension; angina; post-MI; portal hypertension; CHF; NYHA; hepatic-caution; asthma-avoid; Schedule H
VERSION
RxIndia v1.0 — 19 Jan 2026
REFERENCES
• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Cardiovascular Drug Protocols
• Indian Heart Journal — Management of Heart Failure Guidelines
• Cardiological Society of India Guidelines
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• COPERNICUS Trial (for CHF mortality benefit)
• COMET Trial (carvedilol vs metoprolol in CHF)
• CAPRICORN Trial (post-MI LV dysfunction)
• Indian hepatology specialist protocols (for portal hypertension use)
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• API Textbook of Medicine
• AIIMS Cardiovascular Drug Protocols
• Indian Heart Journal — Management of Heart Failure Guidelines
• Cardiological Society of India Guidelines
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• COPERNICUS Trial (for CHF mortality benefit)
• COMET Trial (carvedilol vs metoprolol in CHF)
• CAPRICORN Trial (post-MI LV dysfunction)
• Indian hepatology specialist protocols (for portal hypertension use)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.